PMID- 30585337
OWN - NLM
STAT- MEDLINE
DCOM- 20190320
LR  - 20190320
IS  - 1365-2710 (Electronic)
IS  - 0269-4727 (Linking)
VI  - 44
IP  - 2
DP  - 2019 Apr
TI  - The effect of alpha-lipoic acid on inflammatory markers and body composition in 
      obese patients with non-alcoholic fatty liver disease: A randomized, 
      double-blind, placebo-controlled trial.
PG  - 258-267
LID - 10.1111/jcpt.12784 [doi]
AB  - WHAT IS KNOWN AND OBJECTIVE: Non-alcoholic fatty liver disease (NAFLD) is the 
      most common cause of chronic liver injury. Some animal studies suggest that 
      alpha-lipoic acid (ALA) can improve disease outcome. The aim of this study was to 
      investigate the effects of ALA supplementation on liver enzymes and inflammatory 
      markers in obese patients with NAFLD. METHODS: In the current randomized, 
      double-blind, placebo-controlled clinical trial, 50 obese patients with NAFLD 
      were randomly allocated to either "ALA"(received 1200 mg ALA as two capsules per 
      day plus 400 mg vitamin E) or "placebo"(received placebo containing starch, as 
      two capsules per day plus 400 mg vitamin E) groups for 12 weeks. Body composition 
      and anthropometric measures, serum levels of liver enzymes, adiponectin, 
      interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1) and ferritin 
      were measured at baseline and the end of the study. RESULTS AND DISCUSSION: A 
      total number of 45 patients completed the study (ALA group = 23; placebo 
      group = 22). The serum concentration of IL-6 decreased significantly in ALA group 
      in comparison with the placebo group, at end of the study (P = 0.049). 
      Furthermore, ALA intake resulted in a significant increase in serum adiponectin 
      levels compared to placebo (P = 0.008). A significant improvement was observed in 
      liver steatosis grade of the patients in both groups, compared to baseline 
      (P < 0.05). However, there was no difference between the two groups for the 
      changes in liver steatosis, by the end of the study. Body composition and 
      anthropometric measures, liver enzymes, MCP-1 and ferritin serum levels were not 
      significantly different between the study groups, neither at the baseline nor at 
      the end of the study. WHAT IS NEW AND CONCLUSION: Collectively, ALA 
      supplementation improved serum adiponectin and IL-6 levels, without changing 
      serum liver enzymes and liver steatosis in obese patients with NAFLD.
CI  - (c) 2018 John Wiley & Sons Ltd.
FAU - Hosseinpour-Arjmand, Sonya
AU  - Hosseinpour-Arjmand S
AD  - Student Research Committee, School of Nutrition and Food Sciences, Tabriz 
      University of Medical Sciences, Tabriz, Iran.
FAU - Amirkhizi, Farshad
AU  - Amirkhizi F
AD  - Department of Nutrition, School of Public Health, Zabol University of Medical 
      Sciences, Zabol, Iran.
FAU - Ebrahimi-Mameghani, Mehrangiz
AU  - Ebrahimi-Mameghani M
AD  - Nutrition Research Center, School of Nutrition and Food Sciences, Tabriz 
      University of Medical Sciences, Tabriz, Iran.
LA  - eng
GR  - 5/71/433/Tabriz University of Medical Sciences/
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20181225
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 0 (Adiponectin)
RN  - 0 (Biomarkers)
RN  - 0 (Interleukin-6)
RN  - 1406-18-4 (Vitamin E)
RN  - 73Y7P0K73Y (Thioctic Acid)
SB  - IM
MH  - Adiponectin/blood
MH  - Adult
MH  - Biomarkers/metabolism
MH  - Body Composition/drug effects
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Inflammation/*drug therapy
MH  - Interleukin-6/blood
MH  - Male
MH  - Middle Aged
MH  - Non-alcoholic Fatty Liver Disease/*drug therapy/physiopathology
MH  - Obesity/*physiopathology
MH  - Thioctic Acid/*administration & dosage/pharmacology
MH  - Vitamin E/administration & dosage
OTO - NOTNLM
OT  - adiponectin
OT  - alpha-lipoic acid
OT  - inflammation
OT  - liver enzymes
OT  - non-alcoholic fatty liver
OT  - obesity
EDAT- 2018/12/27 06:00
MHDA- 2019/03/21 06:00
CRDT- 2018/12/27 06:00
PHST- 2018/08/25 00:00 [received]
PHST- 2018/11/02 00:00 [revised]
PHST- 2018/11/18 00:00 [accepted]
PHST- 2018/12/27 06:00 [pubmed]
PHST- 2019/03/21 06:00 [medline]
PHST- 2018/12/27 06:00 [entrez]
AID - 10.1111/jcpt.12784 [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 2019 Apr;44(2):258-267. doi: 10.1111/jcpt.12784. Epub 2018 Dec 
      25.